Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEAT: Epzicom vs Truvada with Kaletra in HIV-1
NCT00244712Phase 4Completed
- Sponsor
- GSK
- Start
- Jul 2005
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial of abacavir + lamivudine in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by GSK. Primary endpoint: Percentage of Participants With HIV-1 RNA <50 Copies/mL at 48 weeks. Started Jul 2005; status: completed.
02
Drugs
abacavir + lamivudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00244712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00244712.